Physician

Venkatesh K Nadar, MD

According to 2025 Medicare claims, Venkatesh Nadar, MD (NPI: 1154383826) practices cardiology in the Harrisburg-Carlisle, PA market, with the plurality of this provider's patient population coming from Cumberland, PA. This provider's primary affiliated billing organization is LEWIN & NADAR ASSOCIATES LLP (NPI: 1821007774; TIN: 731726550) and primary practice location at 17011-2203. Nadar is affiliated with the WellSpan Population Health Services (ACO ID: A2500), participating under the MSSP model.

Nadar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 788 traditional Medicare patients, billed 3,650 HCPCS/CPT codes, and received $242,775 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 4,511 prescription claims across 586 beneficiaries totaling $939,607 in drug costs, led by Eliquis (Apixaban). 2021 DME data shows 26 claims. Open Payments data shows 340 records totaling $2,972,738. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $161,433 to $939,607. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,844	4,111	$133,624
2016	2,523	4,044	$128,993
2017	1,665	3,056	$146,762
2018	857	1,836	$126,698
2019	697	1,708	$123,747
2020	551	1,203	$91,101
2021	806	1,554	$119,705
2022	726	1,428	$122,893
2023	541	3,209	$175,871
2024	788	3,650	$242,775

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	319	2,055	$161,433
2016	319	1,228	$77,884
2017	202	652	$68,308
2018	217	730	$86,425
2019	285	819	$106,133
2020	207	723	$143,202
2021	251	747	$150,435
2022	314	1,109	$157,881
2023	480	3,210	$634,914
2024	586	4,511	$939,607

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	24	$1,003
2020	N/R	36	$1,997
2021	N/R	26	$1,529
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	358	366	$135
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	217	234	$127
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	132	132	$108
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	126	286	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	399	721	$82

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	313	18,945	$349,016
Xarelto	Rivaroxaban	160	8,836	$157,338
Multaq	Dronedarone Hcl	63	3,900	$95,983
Entresto	Sacubitril/Valsartan	79	4,520	$93,656
Repatha Sureclick	Evolocumab	59	2,772	$51,882

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	193	$7,662	Alnylam Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	147	$2,965,076	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Venkatesh K. Nadar, MD?

Tedicare shows public-source Medicare data for Venkatesh K. Nadar, MD (NPI 1154383826), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Venkatesh K. Nadar, MD have ACO affiliation data?

Venkatesh K. Nadar, MD is shown with ACO affiliation data for WellSpan Population Health Services (MSSP, ACO ID A2500).

What billing organization is linked to Venkatesh K. Nadar, MD?

Venkatesh K. Nadar, MD is linked to LEWIN & NADAR ASSOCIATES LLP (billing NPI 1821007774) in the available physician profile data.

Does Venkatesh K. Nadar, MD have Open Payments data?

Venkatesh K. Nadar, MD has 340 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.